All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L1 - all population, immune chekpoint inhibitors vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 9LA, 2021 0.69 [0.55; 0.87]
EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (DT ; all population), 2020 0.94 [0.80; 1.11]
ORIENT-11, 2020 0.61 [0.40; 0.93]
0.79 [0.67 ; 0.95 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 5 67% 3,316 moderate serious deaths (OS) (extension)detailed results CheckMate 9LA, 2021 0.66 [0.55; 0.80]
0.66 [0.55 ; 0.80 ] CheckMate 9LA, 2021 1 0% 719 NA not evaluable PFS (extension)detailed results CheckMate 9LA, 2021 0.68 [0.57; 0.82]
0.68 [0.57 ; 0.82 ] CheckMate 9LA, 2021 1 0% 719 NA not evaluable progression or deaths (PFS)detailed results CheckMate 9LA, 2021 0.70 [0.57; 0.86]
EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
ORIENT-11, 2020 0.48 [0.36; 0.64]
0.59 [0.49 ; 0.72 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, ORIENT-11, 2020 3 55% 1,826 moderate not evaluable objective responses (ORR)detailed results CheckMate 9LA, 2021 1.80 [1.31; 2.48]
EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
ORIENT-11, 2020 2.54 [1.63; 3.97]
2.09 [1.70 ; 2.57 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, ORIENT-11, 2020 3 0% 1,826 moderate not evaluable AE (any grade)detailed results EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (DT ; all population), 2020 0.51 [0.27; 0.96]
ORIENT-11, 2020 1.02 [0.03; 30.46]
0.38 [0.18 ; 0.82 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 4 77% 2,538 moderate not evaluable AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (DT ; all population), 2020 1.02 [0.76; 1.37]
ORIENT-11, 2020 1.13 [0.74; 1.73]
0.65 [0.32 ; 1.34 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 4 94% 2,538 moderate not evaluable AE leading to death (grade 5)detailed results EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (DT ; all population), 2020 2.19 [1.17; 4.11]
ORIENT-11, 2020 0.31 [0.11; 0.90]
0.97 [0.44 ; 2.14 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 4 72% 2,538 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (DT ; all population), 2020 1.43 [0.97; 2.10]
ORIENT-11, 2020 0.70 [0.31; 1.55]
1.06 [0.68 ; 1.64 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 4 61% 2,538 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
MYSTIC (DT ; all population), 2020 2.14 [1.32; 3.47]
ORIENT-11, 2020 0.64 [0.26; 1.56]
1.24 [0.65 ; 2.36 ] MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 3 70% 1,841 moderate not evaluable STRAE (any grade)detailed results CheckMate 9LA, 2021 1.94 [1.36; 2.76]
MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (DT ; all population), 2020 1.52 [1.03; 2.24]
1.20 [0.60 ; 2.40 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 89% 2,151 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.95 [1.33; 2.84]
MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
MYSTIC (DT ; all population), 2020 1.43 [0.92; 2.21]
1.13 [0.53 ; 2.40 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 88% 2,151 moderate not evaluable TRAE (any grade)detailed results CheckMate 9LA, 2021 1.55 [0.94; 2.55]
MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (DT ; all population), 2020 0.31 [0.22; 0.44]
0.48 [0.18 ; 1.29 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 95% 2,151 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.44 [1.06; 1.94]
MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (DT ; all population), 2020 0.55 [0.39; 0.77]
0.65 [0.28 ; 1.51 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 95% 2,151 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 9LA, 2021 1.14 [0.38; 3.43]
MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (DT ; all population), 2020 1.91 [0.47; 7.71]
1.20 [0.55 ; 2.61 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,151 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 9LA, 2021 3.18 [1.94; 5.19]
MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (DT ; all population), 2020 1.47 [0.92; 2.35]
1.39 [0.54 ; 3.55 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 90% 2,151 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 9LA, 2021 3.48 [2.00; 6.05]
MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
MYSTIC (DT ; all population), 2020 2.95 [1.51; 5.78]
2.47 [1.40 ; 4.37 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 55% 2,151 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.88 [0.41; 149.53]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
4.76 [0.80 ; 28.38 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,151 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.06 ; 15.24 ] MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,444 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.37 [0.22; 0.63]
MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.05 [0.00 ; 0.78 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 82% 2,151 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.36 [0.09; 1.37]
MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
MYSTIC (DT ; all population), 2020 0.06 [0.00; 1.01]
0.21 [0.07 ; 0.60 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,151 moderate not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 9.87 [0.54; 181.39]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
5.14 [1.04 ; 25.43 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 4 0% 2,848 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.97 [0.02; 49.27]
MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
MYSTIC (DT ; all population), 2020 0.47 [0.02; 14.16]
0.58 [0.07 ; 4.48 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,151 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.97 [0.24; 3.93]
MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
MYSTIC (DT ; all population), 2020 0.95 [0.24; 3.82]
0.76 [0.31 ; 1.87 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,151 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.41 [0.11 ; 18.45 ] MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,444 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.06 [1.59; 31.30]
EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
MYSTIC (DT ; all population), 2020 4.35 [0.93; 20.28]
ORIENT-11, 2020 0.49 [0.01; 24.91]
2.71 [1.00 ; 7.33 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 5 15% 3,245 moderate serious Fatigue TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 3.97 [0.84; 18.81]
MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
MYSTIC (DT ; all population), 2020 1.09 [0.39; 3.03]
1.30 [0.58 ; 2.92 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 28% 2,151 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.38 [0.60; 3.15]
1.38 [0.60 ; 3.15 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
4.29 [0.68 ; 27.08 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.01 [0.15 ; 6.68 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 4 0% 2,538 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.41 [0.11 ; 18.45 ] MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,444 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.95 [0.07; 58.39]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
ORIENT-11, 2020 0.49 [0.01; 24.91]
2.21 [0.48 ; 10.15 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 5 0% 3,245 moderate serious Increase AST TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.75 [0.15 ; 19.96 ] EMPOWER lung1 (all population), 2021, ORIENT-11, 2020 2 0% 1,094 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 2.46 [0.47; 12.75]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.93 [0.48 ; 7.72 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, ORIENT-11, 2020 3 0% 1,801 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.55 [2.24; 25.47]
7.55 [2.24 ; 25.47 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 4.93 [0.57; 42.41]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
3.77 [0.61 ; 23.22 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021 2 0% 1,404 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.63 [0.39; 6.89]
MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
MYSTIC (DT ; all population), 2020 0.16 [0.02; 1.30]
0.35 [0.05 ; 2.50 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 62% 2,151 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.96 [0.10 ; 9.20 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.71 [0.41; 1.24]
MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.20]
0.07 [0.00 ; 1.34 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 88% 2,151 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
MYSTIC (DT ; all population), 2020 7.74 [0.96; 62.17]
ORIENT-11, 2020 0.98 [0.09; 10.96]
3.18 [0.96 ; 10.52 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 4 0% 2,538 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 5.89 [0.29; 118.02]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.60 [0.26 ; 9.78 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 4 0% 2,548 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 11.88 [0.66; 213.53]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
ORIENT-11, 2020 0.16 [0.02; 1.56]
1.59 [0.36 ; 7.07 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 5 38% 3,245 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.09 [0.44; 2.70]
MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.11 [0.01 ; 2.18 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 82% 2,151 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.17 [0.35; 3.88]
MYSTIC (D ; all population), 2020 0.07 [0.00; 1.18]
MYSTIC (DT ; all population), 2020 0.07 [0.00; 1.18]
0.24 [0.03 ; 2.19 ] CheckMate 9LA, 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 65% 2,151 moderate not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Alopecia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.52 [0.07 ; 4.08 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Anaemia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.03 [0.01; 0.13]
MYSTIC (D ; all population), 2020 0.16 [0.07; 0.34]
MYSTIC (DT ; all population), 2020 0.12 [0.05; 0.28]
0.10 [0.05 ; 0.22 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 47% 2,141 moderate not evaluable Arthralgia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Asthenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.95 [0.41; 2.23]
MYSTIC (DT ; all population), 2020 0.86 [0.36; 2.05]
0.89 [0.49 ; 1.61 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Back pain AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.32 [0.03; 3.05]
MYSTIC (DT ; all population), 2020 0.63 [0.10; 3.80]
0.48 [0.13 ; 1.77 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Blood creatinine increased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Constipation AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 0.95 [0.06; 15.31]
MYSTIC (DT ; all population), 2020 1.90 [0.17; 21.07]
1.32 [0.25 ; 6.88 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Cough AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
1.42 [0.11 ; 18.46 ] MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,444 moderate not evaluable Decreased appetite AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
MYSTIC (D ; all population), 2020 1.44 [0.40; 5.14]
MYSTIC (DT ; all population), 2020 1.43 [0.40; 5.11]
1.38 [0.59 ; 3.25 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.16 [0.02; 1.32]
MYSTIC (D ; all population), 2020 0.38 [0.07; 1.96]
MYSTIC (DT ; all population), 2020 2.12 [0.73; 6.17]
0.61 [0.12 ; 2.98 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 67% 2,141 moderate not evaluable Dyspnoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.17; 21.41]
MYSTIC (D ; all population), 2020 1.61 [0.58; 4.47]
MYSTIC (DT ; all population), 2020 1.11 [0.37; 3.33]
1.40 [0.68 ; 2.85 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Fatigue AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.72 [0.16; 3.24]
MYSTIC (D ; all population), 2020 1.20 [0.47; 3.07]
MYSTIC (DT ; all population), 2020 1.31 [0.52; 3.31]
1.15 [0.63 ; 2.10 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.06 [0.00; 1.03]
0.06 [0.00 ; 1.03 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Hypertension AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increase AST AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 4.87 [0.57; 41.91]
4.87 [0.57 ; 41.91 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increased ALT AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64]
5.82 [0.29 ; 116.64 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Leucopenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.10 [0.01; 0.83]
0.10 [0.01 ; 0.83 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable myocarditis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Nausea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.12 [0.01; 2.26]
MYSTIC (D ; all population), 2020 0.16 [0.02; 1.31]
MYSTIC (DT ; all population), 2020 0.63 [0.18; 2.25]
0.37 [0.13 ; 1.04 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Neutropenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.05 [0.01; 0.21]
MYSTIC (D ; all population), 2020 0.07 [0.02; 0.24]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.05 [0.02 ; 0.13 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Pancytopenia (AE grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
0.96 [0.06 ; 15.46 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pneumonia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.77 [0.20; 2.88]
0.77 [0.20 ; 2.88 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pneumonitis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pruritus AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.06 ; 15.24 ] MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,444 moderate not evaluable Pyrexia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 5.76 [0.29; 115.45]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
2.96 [0.27 ; 32.07 ] MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,444 moderate not evaluable Rash AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
2.47 [0.54 ; 11.26 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Rash maculopapular AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Stomatitis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.02 [0.00; 0.30]
MYSTIC (D ; all population), 2020 0.05 [0.01; 0.38]
MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.03 [0.01 ; 0.13 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Vomiting AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.12 [0.01; 2.26]
MYSTIC (D ; all population), 2020 0.54 [0.16; 1.86]
MYSTIC (DT ; all population), 2020 0.13 [0.02; 1.09]
0.33 [0.12 ; 0.90 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Weight decreased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
MYSTIC (DT ; all population), 2020 2.86 [0.30; 27.64]
2.67 [0.63 ; 11.38 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 18:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 36
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743